Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor ImmunityEva Sum, Pablo Umaña, Moritz Rapp et al.|Clinical Cancer Research|2021Cited by 70
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapyJohannes Sam, Pablo Umaña, Sylvia Herter et al.|Blood|2024Cited by 40
Supplementary Table 1 from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor ImmunityEva Sum, Pablo Umaña, Moritz Rapp et al.|Unknown|2023Cited by 0
Supplementary Table 2 from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor ImmunityEva Sum, Pablo Umaña, Moritz Rapp et al.|Unknown|2023Cited by 0
Supplementary material and methods from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor ImmunityEva Sum, Pablo Umaña, Moritz Rapp et al.|Unknown|2023Cited by 0